US FDA grants breakthrough status to Dizal’s sunvozertinib
This designation is based on results from the global multi-center Phase I/II study, WU-KONG1. The BTD was awarded following the presentation of results at the 2023 ESMO conference,
The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives